

1. Title: Epidemiology of 869,220 varicose vein surgeries over 12 years in Brazil: trends, costs and mortality rate.

Short title: Epidemiology of 869220 varicose vein surgeries

Marcela Juliano Silva^a MD, Andressa Cristina Sposato Louzada^{*a} MD, Marcelo Fiorelli Alexandrino da Silva^a MD, Maria Fernanda Cassino Portugal^a MD, Marcelo Passos Teivelis^{a,b} MD, PhD, Nelson Wolosker^{a,b,c} MD, PhD.

a. Hospital Israelita Albert Einstein

Address: Av. Albert Einstein, 627, Bloco A1, sala 423; ZIP Code 05652-900. Morumbi, São Paulo – SP, Brazil.

b. Faculdade Israelita de Ciências da Saúde Albert Einstein

Address: Av. Prof. Francisco Morato, 4293; Zip Code 05521-200. Butantã, São Paulo - SP, Brazil.

c. São Paulo University Medical School

Address: Av. Dr. Arnaldo, 455; Zip Code 01246903. Cerqueira César, - São Paulo, SP, Brazil.

Institution where the work was done: Hospital Israelita Albert Einstein

Correspondence to: Andressa Cristina Sposato Louzada

Affiliation: Hospital Israelita Albert Einstein –Vascular and Endovascular Surgery

Division - São Paulo, SP, Brazil.

Postal address: Av. Albert Einstein, 627, Bloco A1, sala 423; ZIP Code 05652-900.

Morumbi, São Paulo – SP, Brazil.

E-mail address: drelouzada@gmail.com

Phone number: +55 11 2151-5423

2. Structured Abstract

Objectives: to assess the total numbers of surgical procedures performed between 2008 and 2019 for the treatment of varicose veins in the Public Health System, which exclusively insures more than 160 million Brazilians, the distribution of surgeries over time, as well as its costs and mortality rates.

Study design: retrospective cross-sectional population-based study

Materials and Methods: public and open data referring to all surgeries to treat chronic venous disease between 2008 and 2019 were extracted from the database of the Brazilian Public Health System.

Results: In total, 869,220 surgeries were performed to treat chronic venous disease in public hospitals and outpatient clinics in Brazil, with an average rate of 4.5 surgeries per 10,000 inhabitants per year. From 2015 on, we observed a slight downward trend in the total number of procedures. The total amount reimbursed by the government was US\$ 232,775,518.11. A total of 49 deaths were registered following varicose vein surgery, corresponding to a mortality rate of 0.0056%.

Conclusions: a total of 869,220 surgeries performed to treat chronic venous disease over twelve years, with an overall rate of 4.52 procedures per 10,000 inhabitants per year. The mortality rate was very low, 0.0056%.

3. Key words: varicose veins, varicose vein surgery, big data, epidemiology, chronic venous disease, chronic venous insufficiency

4. Abbreviation List

Chronic venous disease	CVD
United States of America	USA
Brazilian Public Health System	SUS

5. Introduction

Chronic venous disease (CVD) is very prevalent, progressive¹ and with relevant morbidity^{2,3}, leading to a high social, economic, and health burden⁴⁻⁷.

The prevalence of CVD may be even greater than 50% of the population⁸⁻¹⁰ and both the prevalence and the severity of CVD are expected to increase as the population ages^{11,12}. Impairment of the patient's health and quality of life is evident in the advanced stages of the CVD, especially when they present with venous ulcers¹³. However, patients report poorer health-related quality of life even with uncomplicated CVD³.

Furthermore, CVD represents a high social and economic burden. In the United States, CVD leads to 2 million workdays missed each year and to early retirement⁴, with a nationwide health care burden of more than \$3 billion per year⁵. In Brazil, between 2005 and 2014, social security expenses with temporary disability due to CVD increased 3.5-fold, and more than 27 million workdays were lost⁶.

The standard surgical treatment, which includes ligation and stripping of saphenous veins as well as varicose veins' phlebectomies, is cost-effective¹⁴⁻¹⁷. Even though this is a well-established and widely performed procedure to treat such a prevalent and morbid disease, to our knowledge, only a few countries have nationwide studies analyzing procedure rates and mortality, namely: Japan, the United States of America (USA) and Portugal, all of three developed countries. In Japan, they observed 41,246 surgeries for the treatment of CVD in 2014, with zero 30-day mortality¹⁸. In the USA, a total of 48,615 surgeries for CVD was performed between 2005 and 2017, with a 30-day mortality rate of 0.02%¹⁹. In Portugal, 153,382 patients underwent surgery to treat CVD in public hospitals between 2004 and 2016, with an in-hospital mortality rate of 0.015%²⁰.

We believe that only population-level data generate real-world evidence, better supporting health care analysis and planning. To that aim, series larger and more diversified than those mentioned above may be necessary, including data from developing countries as well, which are lacking in the current literature.

Therefore, the objective of the present study was to retrospectively assess the total numbers of surgical procedures performed between 2008 and 2019 for the treatment of CVD in the Brazilian Public Health System (SUS), which exclusively insures more than 160 million Brazilians, the distribution of the surgeries over time, as well as its costs and mortality rates.

6. Materials and methods:

Data were retrieved from the TabNet platform²¹, a public health information application developed by DATASUS, the Health Informatics Department of the Brazilian Ministry of Health. The TabNet system provides open data regarding procedures performed within the Brazilian Public Health System, input by hospitals and outpatient clinics adequately accredited. This accreditation and the information registration are a prerequisite for governmental reimbursement for the procedures performed.

Information on surgeries to treat CVD was selected from 2008 to 2019 at the TabNet platform of Brazil. Data included geographic region, number of procedures performed, mortality within the index admission in the hospital or in the outpatient facility, and the amounts reimbursed by the Public Health System.

Two types of procedure were assessed, according to coding as established by the management system for procedures and medications of the Brazilian Public Health System - SIGTAP (Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM): bilateral surgical treatment for CVD (04.06.02.056-6) and unilateral surgical treatment for CVD (04.06.02.057-4).

All data were collected from public access sites through computer programs of automated content access (web scraping). These automated navigation codes were programmed in Python language (v. 2.7.13, Beaverton – Oregon – USA) using the Windows 10 Single Language operational system. The data collection, platform field selection, and table adjustment steps were performed using the selenium-webdriver packages (v. 3.1.8, Selenium HQ, several collaborators worldwide) and pandas (v. 2.7.13, Lambda Foundry, Inc. e PyData Development Team, New York, USA). The Mozilla Firefox browser (v. 59.0.2, Mountain – California – USA) and geckodriver webdriver (v. 0.18.0, Mozilla Corporation, Bournemouth, England) were used.

Following collection and treatment, data were organized and grouped in spreadsheets using the Microsoft Office Excel 2016® (v. 16.0.4456.1003, Redmond – Washington – USA) software.

Reimbursement amounts in Brazilian Real (R\$, the official Brazilian currency) were converted into US dollars (US\$) using the exchange rate on December 31st, 2013 (US\$1 = R\$2.34), the median date between the first and last cases evaluated.

Standardized procedure rates were calculated by dividing the number of procedures by the years of study and by the population exclusively insured by SUS, and then multiplying the quotient per 10,000.

Statistical analysis: trends were evaluated using linear regression. For all tests, a p-value less than or equal to 0.05 was considered statistically significant.

This study was approved by the Ethics Committee of the institution where it was carried out (CAAE: 35826320.2.0000.0071). All data provided by DATASUS and TabNet is open and de-identified. For this reason, the Institutional Review Board exempted informed consent.

Data availability statement: data associated with the paper are available in DATASUS TabNet platform²¹.

7. Results:

In total, 869,220 surgeries were performed to treat CVD in Brazilian public hospitals and outpatient clinics between 2008 and 2019. The number and frequency of CVD surgery throughout the years are shown in Table 1. Bilateral procedures were the most frequently performed, representing 61.68% of the surgeries.

The distribution of procedures rates per 10,000 inhabitants exclusively dependent on the public health system per year is shown in Graph 1. The overall average rate was 4.5 surgeries for CVD treatment per 10,000 populations per year. The year 2014 showed the highest rates. From 2015 on, we observe a slight downward trend in the surgery rates ($p=0.054$).

The total amount reimbursed by the government per CVD surgeries between 2008 and 2019 was US\$ 232,775,518.11. The overall average investment per surgery was US\$ 267.80.

Total procedures, total deaths, and mortality rates among Brazilian geographic regions are presented in Table 2. A total of 49 deaths within the index admission in the hospital or outpatient facility was registered following CVD surgery, representing an overall mortality rate of 0.0056%.

The southeast region of Brazil performed more than half of the procedures and showed an intermediate mortality rate. Both the South and the Southeast had the higher

standardized rates of CVD surgery per year per 10,000 populations, with rates more than 3 times higher than the ones observed in the North and Northeast.

8. Discussion:

We observed a total of 869,220 surgeries to treat CVD, which corresponds to the largest series of the mostly performed vascular surgery.

Bilateral procedures were more frequent, which is likely a reflection of public reimbursement and logistics in Brazil, as waiting lines are frequently long.

The overall standardized rate was 4.5 surgeries for CVD treatment per 10,000 populations per year, which is similar to the ones observed in Japan¹⁸ and in the United States when considering the Medicare enrollees²², but at least 5 times smaller than the ones reported in some European countries such as Finland²³, Belgian²⁴, and Scotland²⁵. Since the Brazilian prevalence of CVD is estimated to be high, 37.9% in men and 50.9% in women²⁶, the 5-fold higher rates of surgical procedures in these European countries can not be explained by a higher prevalence in a similar fashion. Health care is mostly publicly funded in Brazil, Finland²⁷, Belgium²⁸ and Scotland²⁹, therefore payment source can not explain the difference either. A possibility to be studied is that the population of these European countries is much smaller than that of Brazil, the United States of America and Japan, so perhaps the logistics of treating a low-mortality disease such as CVD are easier.

We also observed a disparity internally, as the South and Southeast, the two regions with the highest population density and development indexes, had CVD surgery rates more than 3 times higher than the ones observed in the North and Northeast, the poorest and least developed Brazilian regions³⁰, which may suggest an impact of socioeconomic factors on the surgical treatment of CVD.

Regarding the distribution of surgeries over time, in Brazil, we observed a slight decrease in the total surgical procedures performed under the Public Health System since 2015. This finding contrasts with recent reports in the literature of a rising tendency to treat CVD surgically^{18,24,25}. One possible explanation may be an increasing rate of ultrasound-guided sclerotherapy with polidocanol foam to treat CVD, an outpatient procedure that is also reimbursed by the Brazilian government but was not evaluated in

our study. Concerning endovenous procedures, although they may be accounted for an upward trend in procedures performed to treat CVD in other countries currently^{18,22}, they are unlikely to influence the standard surgery rates in Brazil, as SUS does not ordinarily reimburse them. Some patients may be seeking treatment for CVD in the private sector, as the waiting lists are often long in SUS, but these patients probably do not represent a large sample, since most Brazilians exclusively insured by the SUS cannot afford to pay surgical treatments out of their pockets.

The average spent by the government per procedure was US\$ 267.80. The average amount paid by the governments of China³¹ and the United Kingdom¹⁴ per surgery is at least twice as much the amount paid by the Brazilian government. Due to the limitations of the data collection, we were not able to distinguish the amount paid for unilateral and bilateral surgeries, or for inpatient or outpatient procedures, we only have access to an average amount. Moreover, the government's refund is based on a fixed compensation table and may not reflect the actual hospital and outpatient expenses, which is another limitation of our study.

After the 869,220 surgeries performed to treat CVD, we observed 49 deaths within the index admission in the hospital or in the outpatient facility, corresponding to a mortality rate of 0.0056%. To our knowledge, the only other population-based study for comparison was the one evaluating the data from Portuguese public hospitals, with an in-hospital mortality rate of 0.015%²⁰. The mortality rate for CVD surgeries in Portugal was three-fold higher. A possible explanation for this difference is that our series is almost six-fold larger, maybe better reflecting real-life statistics. Another explanation is that in Portugal, the surgery rate for CVD is more than double the one in Brazil, thus it is possible that they encompass more at-risk patients in Portugal. Nonetheless, both mortality rates are very low, which underlines the safety of the surgical treatment.

Still regarding mortality assessment, some limitations of our study are noteworthy. As our data are anonymous, we do not know the causes of death and follow-up is not possible, therefore, deaths after discharge were missed, and we are unable to calculate 30-day mortality, as authors evaluated in Japan¹⁸ and USA¹⁹. Consequently, we may be observing more deaths related to anesthetics and bleeding complications and perhaps missing some pulmonary embolism-related deaths.

Limitations:

In addition to the limitations already mentioned: the inability to distinguish the amount paid for unilateral and bilateral surgeries and the surgeries which involved or not saphenous vein treatment, refund based on a fixed compensation table and the impossibility to follow up, some other limitations are worthy of note.

We only have data on total number of procedures performed, which possibly does not reflect the number of patients treated, as some patients may have undergone more than one procedure to treat CVD, such as two unilateral procedures or even re-interventions considering that the study period is large.

As inherent to a retrospective analysis using web scraping data collection, our study is limited by the loss of patient information and eventual miscoding of the administrative database, which should not be statistically significant, given the large size of our population.

Despite these limitations, this is a comprehensive analysis of the surgical treatment of CVD under the Brazilian Public Health System, with the largest series of the most frequently performed vascular surgery in the literature, granting real-life statistics with high external validity. Therefore we believe this study presents a valuable tool for a better understanding of the surgical management of CVD and highlights its safety in the real world.

Conclusions:

We observed a total of 869,220 surgeries performed to treat CVD over twelve years, with an overall rate of 4,52 procedures per 10,000 inhabitants per year. The mortality rate was very low, 0.0056%.

9. Acknowledgements and Declarations

We thank Sergio Kuzniec, M.D. Ph.D. for his critical reading of the manuscript.

This study was approved by the Ethics Committee of the institution where it was carried out (CAAE: 35826320.2.0000.0071).

No author has conflict of interest, and this research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

All authors have seen and approved this manuscript.

Authors' contributions:

Conception and design: MPT, NW

Data collection: MJS, ACSL, MFAS, MFCP

Analysis and interpretation: MJS, ACSL, MFAS, MFCP, MPT, NW

Writing the article: MJS, ACSL, MFAS, MFCP

Critical revision of the article: MJS, ACSL, MFAS, MFCP, MPT, NW

Final approval of the article: MJS, ACSL, MFAS, MFCP, MPT, NW

Overall responsibility: MJS, ACSL, MFAS, MFCP, MPT, NW

10. References:

1. Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FGR, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. *J Vasc Surg Venous Lymphat Disord*. 2015 Jan;3(1):18–26.
2. Chang S-L, Huang Y-L, Lee M-C, Hu S, Hsiao Y-C, Chang S-W, et al. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. *JAMA*. 2018 Feb 27;319(8):807.
3. Darvall KAL, Bate GR, Adam DJ, Bradbury AW. Generic Health-related Quality of Life is Significantly Worse in Varicose Vein Patients with Lower Limb Symptoms Independent of Ceap Clinical Grade. *Eur J Vasc Endovasc Surg*. 2012;4.
4. Kim Y, Png CYM, Sumpio BJ, DeCarlo CS, Dua A. Defining the human and health care costs of chronic venous insufficiency. *Semin Vasc Surg*. 2021 Mar;34(1):59–64.
5. Ruckley CV. Socioeconomic Impact of Chronic Venous Insufficiency and Leg Ulcers. *Angiology*. 1997 Jan;48(1):67–9.

6. da Coelho RM, Nunes MAP, Gomes CVC, dos Viana IS, da Silva ÂM. Time trends and social security burden of temporary work disability due to chronic venous disease in Brazil. *BMC Public Health*. 2020 Dec;20(1):477.
7. Tsai S, Dubovoy A, Wainess R, Upchurch GR, Wakefield TW, Henke PK, et al. Severe Chronic Venous Insufficiency: Magnitude of the Problem and Consequences. *Ann Vasc Surg*. 2005;19(5):7.
8. Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: A population-based study in France. *J Vasc Surg*. 2004 Oct;40(4):650–9.
9. Criqui MH. Chronic Venous Disease in an Ethnically Diverse Population: The San Diego Population Study. *Am J Epidemiol*. 2003 Sep 1;158(5):448–56.
10. Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, et al. Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. *Eur J Vasc Endovasc Surg*. 2017 Dec;54(6):752–8.
11. Davies AH. The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence. *Adv Ther*. 2019 Mar;36(S1):5–12.
12. Porciunculla M de M, Leiderman DBD, Altenfeder R, Pereira CSB, Fioranelli A, Wolosker N, et al. Clinical, ultrasonographic and histological findings in varicose vein surgery. *REV ASSOC MED BRAS*. :7.
13. Joaquim FL, Cruz-Quintana F, Pereira ER. Impact of venous ulcers on patients' quality of life: an integrative review. *Qual Life*. :9.
14. Epstein D, Onida S, Bootun R, Ortega-Ortega M, Davies AH. Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. *Value Health*. 2018 Aug;21(8):911–20.
15. Biemans AAM. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. *J Vasc Surg*. 2013;58(3):9.

16. Michaels J, Campbell W, Brazier J, MacIntyre J, Palfreyman S, Ratcliffe J, et al. The treatment of varicose veins (REACTIV trial). :198.
17. Mendes C, Martins A, Fukuda J, Parente J, Munia M, Fioranelli A, et al. Randomized trial of radiofrequency ablation versus conventional surgery for superficial venous insufficiency: if you don't tell, they won't know. *Clinics*. 2016 Nov 11;71(11):650–6.
18. The Japanese Society for Vascular Surgery Database Management Committee Member, NCD Vascular Surgery Data Analysis Team. Vascular Surgery in Japan: 2014 Annual Report by the Japanese Society for Vascular Surgery. *Ann Vasc Dis*. 2020 Dec 25;13(4):474–93.
19. Kim TI, Zhang Y, Guzman RJ, Ochoa Char CI. Trends of hospital-based surgery for varicose veins in the elderly. *J Vasc Surg Venous Lymphat Disord*. 2021 Jan;9(1):146-153.e2.
20. Castro-Ferreira R, Quelhas MJ, Freitas A, Vidoedo J, Silva EA, Marinho A, et al. Vascular training does matter in the outcomes of saphenous high ligation and stripping. *J Vasc Surg Venous Lymphat Disord*. 2019 Sep;7(5):732–8.
21. Ministry of Health of Brazil. DATASUS [Internet]. [cited 2021 Jul 15]. Available from: <http://www2.datasus.gov.br/DATASUS/index.php?area=02>
22. Prabhakar AM, Misono AS, Sheth RA, Rosenkrantz AB, Hemingway J, Hughes DR, et al. Changing Medicare Utilization of Minimally Invasive Procedures for the Treatment of Chronic Venous Insufficiency. *J Vasc Interv Radiol*. 2017 Jun;28(6):818–24.
23. Laurikka J, Sisto T, Auvinen O, Tarkka M, Laara E, Hakama M. Varicose veins in a Finnish population aged 40-60. *J Epidemiol Community Health*. 1993 Oct 1;47(5):355–7.
24. Guillaume GM, Meeus P, Dalcq V, van der Borgh L, Vuylsteke ME, de Maeseneer MG. Influence of reimbursement policies on phlebological surgical practice in

- Belgium between 2007 and 2017. *Int Angiol* [Internet]. 2020 Oct [cited 2021 Apr 14];39(4). Available from:
<https://www.minervamedica.it/index2.php?show=R34Y2020N04A0267>
25. Galland RB, Whatling PJ, Crook TJ, Magee TR. Regional variation in varicose vein operations in England 1989-1996. *Ann R Coll Surg Engl*. 2000 Jul;82(4):275–9.
 26. Maffei FHA, Magaldi C, PINHOt SZ, Lastoria S, Pinho W, Yoshida WB, et al. Varicose Veins and Chronic Venous Insufficiency in Brazil: Prevalence among 1755 Inhabitants of a Country Town. *Int J Epidemiol*. :8.
 27. Koskinen S, Finlande, Ministry of Social Affairs and Health, National Public Health Institute (Finlande), Finlande, Centre national de recherche et de développement pour les affaires sociales et la santé. *Health in Finland*. Helsinki: National Public Health Institute KTL□: National Research and Development Centre for Welfare and Health STAKES□: Ministry of Social Affairs and Health; 2006.
 28. Schokkaert E, Van de Voorde C. Health care reform in Belgium. *Health Econ*. 2005 Sep;14(S1):S25–39.
 29. Woods KJ. The development of integrated health care models in Scotland. *Int J Integr Care* [Internet]. 2001 Jun 1 [cited 2021 May 3];1(2). Available from:
<http://www.ijic.org/article/10.5334/ijic.29/>
 30. Instituto Brasileiro de Geografia e Estatística. Painel de Indicadores | IBGE [Internet]. [cited 2021 Jul 16]. Available from:
<https://www.ibge.gov.br/indicadores.html>
 31. Zhang M, Qiu T, Bu X, Li X, Liang G, Zhang H, et al. A national survey on management of varicose veins in China. *J Vasc Surg Venous Lymphat Disord*. 2018 May;6(3):338-346.e1.

11. Tables

Table 1: Absolute and relative frequencies of unilateral and bilateral surgeries for varicose veins between 2008 and 2019

Year	Unilateral Procedures		Bilateral Procedures		TOTAL
	n	(%)	n	(%)	
2008	27,484	38.08	44,688	61.92	72,172
2009	25,836	36.05	45,838	63.95	71,674
2010	25,278	33.66	49,817	66.34	75,095
2011	24,625	32.85	50,332	67.15	74,957
2012	24,262	33.07	49,109	66.93	73,371
2013	25,800	34.17	49,698	65.83	75,498
2014	30,181	38.10	49,031	61.90	79,212
2015	26,540	38.62	42,174	61.38	68,714
2016	29,492	42.79	39,431	57.21	68,923
2017	30,494	45.43	36,635	54.57	67,129
2018	35,400	47.23	39,549	52.77	74,949
2019	27,693	41.01	39,833	58.99	67,526
Total	333,085	38.32	536,135	61.68	869,220

Table 2: Absolute and relative mortality by geographic region for varicose vein surgery between 2008 and 2019

Geographic Region	Procedures		Mortality	
	n	Standardized Rate	n	%
North	28,522	1.4	1	0.0035%
Northeast	111,062	1.8	12	0.0108%
Southeast	471,970	6.8	28	0.0059%
South	210,327	7.8	4	0.0019%
Center-West	47,339	3.1	4	0.0084%
Total	869,220	4.5	49	0.0056%

12. Figure legends

Graph 1. Distribution of procedures rates per 10,000 inhabitants exclusively dependent on the public health system per year.

